Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women

Original title: Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women.

By Deanfield, Wong, Katsoulis +6Nature medicineOct 16, 2026

Score█████░░░░░4.7

Key numbers

99.8% tirzepatide
95% confidence interval 15.9 to
15.5% of baseline weight

VerdictWorth a reader's time today.

Read the original

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated substantial weight reduction and cardiometabolic benefit in randomized trials; however, prospective implementation evidence from digital care models and female sex community populations remains limited. Here we report outcomes from an observational study of 8,127 women initiating GLP-1RA therapy (99.8% tirzepatide) through a structured digital program incorporating mandatory biochemical monitoring, weekly video-supported follow-up and clinician-guided dose titration in the UK. Mean weight reduction was 16.1 kg (95% confidence interval 15.9 to 16.2; P < 0.001), representing 15.5% of baseline weight; 83.1% achieved ≥10% and 22.4% achieved ≥20% weight loss, with consistent responses across age, baseline weight and socioeconomic strata. Among participants with paired biomarker data, mean glycated hemoglobin decreased by 3.3 mmol mol-1 (95% confidence interval 3.1 to 3.4; P < 0.001), normalizing in 84.5% of those with baseline diabetes-range values and 96.3% with prediabetes, and lipid parameters improved significantly (reductions in total cholesterol of 0.77 mmol l-1, low-density lipoprotein cholesterol of 0.61 mmol l-1 and triglycerides of 0.47 mmol l-1). Retention was 91.4% at 6 months, with no serious treatment-related adverse events. These findings support the feasibility of delivering structured, digitally enabled obesity pharmacotherapy at scale and provide prospective real-world implementation evidence for this care model. Interpretation is limited by the observational design, absence of a comparator group, self-pay population and 6-month follow-up.

John Deanfield, Jamie Lai Chun Wong, Michail Katsoulis, Emma Deanfield, Raj Thakkar, Riyaz Patel, Rachael Joy, Matthew Noble, Donna H Ryan

The editor's rubric

Heuristic review

Leverage3 / 5: A method or resource many groups across the field will adopt within a year.; 10% of this desk’s rubric
Magnitude2 / 5: Solid incremental gain on a meaningful problem.; 20% of this desk’s rubric
Evidence4 / 5: Strong: large scale, preregistered, independently replicated, or a well-powered randomized trial.; 32% of this desk’s rubric
Novelty3 / 5: A genuinely new approach to an open problem.; 8% of this desk’s rubric
Trajectory2 / 5: Some room to improve with obvious engineering.; 5% of this desk’s rubric
Stakes3 / 5: Meaningful benefit to many people within a few years.; 25% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	███░░ 3	10%	A method or resource many groups across the field will adopt within a year.
Magnitude	██░░░ 2	20%	Solid incremental gain on a meaningful problem.
Evidence	████░ 4	32%	Strong: large scale, preregistered, independently replicated, or a well-powered randomized trial.
Novelty	███░░ 3	8%	A genuinely new approach to an open problem.
Trajectory	██░░░ 2	5%	Some room to improve with obvious engineering.
Stakes	███░░ 3	25%	Meaningful benefit to many people within a few years.

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we report); design (randomized); verification (confidence interval, p-value); scale (scalable); stakes (major disease, prevention or cure). Red flags: weak evidence (preliminary).

How the score was computed

rank-2026-10-18

Score█████░░░░░4.7

Score = 10 × (80% × adjusted merit / 10 + 10% × attention + 10% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 6.1 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 4.9 / 10; Shrunk toward the desk prior by editor confidence (44%).
Attention: 0%; Citations, upvotes, points, mentions.
Freshness: 74%; Half-life decay since publication.

Citations0 (reference 20, via openalex, Oct 20, 2026, 06:17 UTC)

The record

Reviewed by heuristic-v7 on Oct 20, 2026, 06:17 UTC. Paper type: clinical.
Categories: Journal Article
BRIEF, No.4 in the Medicine edition of October 20, 2026.